Brexit Watch: Public Health After Brexit
Listen now
Description
The European Medicines Agency is based in London and is responsible for the safety of medicines developed by pharmaceutical companies for use in the EU. If Article 50 is triggered then the UK will leave the EMA. Dan Damon finds out about the potential impact of this with Professor Sir Michael Rawlins, the chairman of the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. (Photo: Medicine, water and a stethoscope. Credit: Franck Fife/AFP)
More Episodes
In Albania, attempts are now being made to discover the fate of about 6,000 people who went missing during 40 years of Communism. Andrew Hoskens in Tirana speaks to one man whose Catholic priest uncle fell foul of Enver Hoxha's regime. (Photo: Nikolin Kurti at the site of the mass grave he...
Published 10/22/17
Published 10/22/17
Some UK companies see possible gains from exiting the EU. But a survey of 700 British businesses concludes there is widespread uncertainty. Dan speaks to Paul Kenward of British Sugar, and Professor Nicholas Bloom of Stanford University (Photo: An aerial view of London's financial district on...
Published 09/28/17